Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Drug Profile

Sofosbuvir/velpatasvir/voxilaprevir - Gilead Sciences

Alternative Names: GS 9857/sofosbuvir/velpatasvir; GS-5816/GS-9857/sofosbuvir; GS-7977/GS-5816/GS-9857; GS-9857/GS-5816/sofosbuvir; GS-9857/SOF/VEL; GS-9857/VEL/SOF; GS-9857/velpatasvir/sofosbuvir; SOF/GS-9857/VEL; SOF/VEL/GS-9857; SOF/VEL/VOX; Sofosbuvir/GS-5816/GS-9857; Sofosbuvir/GS-9857/velpatasvir; Sofosbuvir/velpatasvir/GS-9857; Sofosbuvir/voxilaprevir/velpatasvir; VEL/GS-9857/SOF; VEL/SOF/GS-9857; Velpatasvir/GS-9857/sofosbuvir; Velpatasvir/sofosbuvir/GS-9857; Velpatasvir/sofosbuvir/voxilaprevir; Velpatasvir/voxilaprevir/sofosbuvir; Vosevi; Voxilaprevir/sofosbuvir/velpatasvir; Voxilaprevir/velpatasvir/sofosbuvir

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 24 Mar 2020 Gilead Sciences terminates phase II trial in Hepatitis C (In adolescents, In children) in Germany, Italy, Poland, United Kingdom (PO) (NCT03820258) (EudraCT2018-000480-87)
  • 30 Dec 2019 Phase-III clinical trials in Hepatitis C (Treatment-naive) in South Korea (PO)(NCT04211909)
  • 30 Dec 2019 Phase-III clinical trials in Hepatitis C (Treatment-experienced) in South Korea (PO)(NCT04211909)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top